Interest in CHIP testing for patient in an introductory vignette at baseline, after disclosure of population-based risks, followed by CHIP-related risks, and then potential management strategies
| Interest in CHIP testing following presentation of... . | Definitely not have the test, n (%) . | Probably not have the test, n (%) . | Probably have the test, n (%) . | Definitely have the test n (%) . | Not available, n (%) . | Change in testing preference∗ compared with… . | Switch from inclined to disinclined, n (%) . | Switch from disinclined to inclined, n (%) . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| Risks | |||||||||
| (1) Vignette alone | 4 (0.8) | 42 (8.0) | 190 (36.0) | 270 (51.1) | 22 (4.2) | — | — | — | — |
| (2) CHIP-independent, population-based risks for BC recurrence, hematologic malignancy, heart disease | 12 (2.3) | 87 (16.5) | 195 (36.9) | 210 (39.8) | 24 (4.6) | Vignette alone (1 vs 2) | 56/504 (11.1) | 3/504 (0.6) | <.001 |
| (3) Increased CHIP-associated risks | 7 (1.3) | 47 (8.9) | 171 (32.4) | 278 (52.7) | 25 (4.7) | CHIP-independent population-based risks for BC recurrence, hematologic malignancy, and heart disease (2 vs 3) | 7/503 (1.4) | 51/503 (10.1) | <.001 |
| Actionability | |||||||||
| (4) Current management strategy | 20 (3.8) | 67 (12.7) | 181 (34.3) | 234 (44.3) | 26 (4.9) | — | — | — | — |
| (5) CHIP clinic | 13 (2.5) | 44 (8.3) | 190 (36.0) | 255 (48.3) | 26 (4.9) | Current management strategy (4 vs 5) | 6/502 (1.2) | 36/502 (7.2) | <.001 |
| (6) Hypothetical treatment for CHIP | 4 (0.8) | 13 (2.5) | 140 (26.5) | 345 (65.3) | 26 (4.9) | Current management strategy (4 vs 6) | 1/502 (0.2) | 71/502 (14.1) | <.001 |
| Interest in CHIP testing following presentation of... . | Definitely not have the test, n (%) . | Probably not have the test, n (%) . | Probably have the test, n (%) . | Definitely have the test n (%) . | Not available, n (%) . | Change in testing preference∗ compared with… . | Switch from inclined to disinclined, n (%) . | Switch from disinclined to inclined, n (%) . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| Risks | |||||||||
| (1) Vignette alone | 4 (0.8) | 42 (8.0) | 190 (36.0) | 270 (51.1) | 22 (4.2) | — | — | — | — |
| (2) CHIP-independent, population-based risks for BC recurrence, hematologic malignancy, heart disease | 12 (2.3) | 87 (16.5) | 195 (36.9) | 210 (39.8) | 24 (4.6) | Vignette alone (1 vs 2) | 56/504 (11.1) | 3/504 (0.6) | <.001 |
| (3) Increased CHIP-associated risks | 7 (1.3) | 47 (8.9) | 171 (32.4) | 278 (52.7) | 25 (4.7) | CHIP-independent population-based risks for BC recurrence, hematologic malignancy, and heart disease (2 vs 3) | 7/503 (1.4) | 51/503 (10.1) | <.001 |
| Actionability | |||||||||
| (4) Current management strategy | 20 (3.8) | 67 (12.7) | 181 (34.3) | 234 (44.3) | 26 (4.9) | — | — | — | — |
| (5) CHIP clinic | 13 (2.5) | 44 (8.3) | 190 (36.0) | 255 (48.3) | 26 (4.9) | Current management strategy (4 vs 5) | 6/502 (1.2) | 36/502 (7.2) | <.001 |
| (6) Hypothetical treatment for CHIP | 4 (0.8) | 13 (2.5) | 140 (26.5) | 345 (65.3) | 26 (4.9) | Current management strategy (4 vs 6) | 1/502 (0.2) | 71/502 (14.1) | <.001 |
CHIP testing inclination for self-dichotomized as inclined (definitely test or probably test) or disinclined (definitely not test or probably not test).